Mr. Andre Larente reports

DIAGNOS ANNOUNCES EXERCISE OF STOCK WARRANTS AND PROVIDES A CASH UPDATE

Diagnos Inc. has noted the exercise of 5,076,922 stock warrants within the past five months. The cash position of the corporation as of today is $1,433,000.

In the coming weeks, the corporation expects to submit a first claim for disbursement under a financing agreement in the form of an interest-free loan of up to $2-million from the government of Quebec to support global commercialization. The financing agreement was initially announced on Sept. 8, 2020.

The corporation has also granted 1.2 million stock options to one of its directors. Stock options vest at 50 per cent per year, commencing with the first anniversary of the grant. The exercise price of these stock options has been established at 56 cents per share. The expiry date to which these stock options can be exercised has been fixed to Feb. 24, 2026.

About Diagnos Inc.

Diagnos is a Canadian corporation with a mission of early detection of critical health issues through the use of its artificial intelligence tool CARA (computer-assisted retina analysis). CARA is a tele-ophthalmology platform that integrates with existing equipment (hardware and software) and processes at the point of care. CARA's AI image enhancement algorithms make standard retinal images sharper, clearer and easier to read. CARA is accessible securely over the Internet, and is compatible with all recognized image formats and brands of fundus cameras, and is electronic health record compatible. CARA is a cost-effective tool for screening large numbers of patients in real-time. CARA complies with local regulations, is FDA (Food and Drug Administration) cleared for commercialization in the United States, is Health Canada licensed for commercialization in Canada and is CE marking compliant in Europe.

We seek Safe Harbor.